HER2+ metastatic breast cancer is a particularly aggressive form of the disease, and currently accounts for about one in every five breast cancer diagnoses. In this moving profile, HER2+ metastatic breast cancer survivor Dr. Kathy Bennett, who was diagnosed with the disease in 2008, and UCLA Jonsson Comprehensive Cancer Center researcher and Herceptin pioneer Dr. Dennis Slamon, discuss how clinical trials turn survivors and scientists into colleagues, uniting them in the fight to stop this deadly disease. From AACR News.